Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493027 | 0.93 | MCL1 (0.43) | AGTR1AGTR2DHODHMRGPRX4 | |
| SCHEMBL6491233 | 0.91 | MRGPRX4 (0.40) | VDRDCTPP1KDM4ENPC1ALDH1A1 | |
| SCHEMBL6487408 | 0.88 | DCTPP1 (0.38) | AGTR1AGTR2VDRDCTPP1KDM4E | |
| SCHEMBL6489503 | 0.86 | CYSLTR1 (0.42) | VDRDCTPP1SMN1; SMN2DHODHMRGPRX4 | |
| SCHEMBL6498787 | 0.85 | BCL2 (0.40) | AGTR1AGTR2DCTPP1 | |
| SCHEMBL6491685 | 0.84 | FABP3 (0.46) | SMN1; SMN2MRGPRX4 | |
| SCHEMBL6488551 | 0.84 | PIK3C2B (0.39) | AGTR1AGTR2DHODH | |
| SCHEMBL6488163 | 0.83 | PIK3C2B (0.37) | AGTR1AGTR2DCTPP1DHODH | |
| SCHEMBL6498198 | 0.82 | DCTPP1 (0.47) | DCTPP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6501530 | 0.82 | GABRA1 (0.39) | AGTR1AGTR2DCTPP1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | AGTR1 2045/4885AGTR2 2247/4885VDR 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.